Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

N Engl J Med. 2015 May 7;372(19):1791-800.

11 May May 2015 10 years ago
  • Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, et al, PEGASUS-TIMI 54 Steering Committee and Investigators. Marenzi G e Rubino M tra i collaboratori
QR Code
The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. The Authors investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in 21,162 patients who had had a myocardial infarction 1 to 3 years earlier.

 In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding.